CGS encourages responsible uses and effecitve governance of human genetic and assisted reproductive technologies

Featured

Commercial DNA, and the China Card

By Pete Shanks | 02.03.2021
Biopolitical Times
On Sunday, January 31, 60 Minutes featured DNA databases and China — together and separately — in fine, bombastic style.
Genomics

CRISPR: What is the future of gene editing? | Start Here

This episode of the Al Jazeera video series Start Here features an interview with CGS Program Director on Genetic Justice, Katie Hasson.
Technologies
Human Genetic Modification
Global Governance
Bioethics
Biopolitics

CGS in 2020

By CGS | 01.07.2021
Biopolitical Times
The last year was extraordinary. It challenged, touched, and changed all of us at the Center for Genetics and Society.
Assisted Reproduction

Heritable Human Genome Editing: Political Implications and Opportunities for Leadership

Internal Content

To: The Biden-Harris Administration

From: Marcy Darnovsky, PhD, Executive Director, Center for Genetics and Society[1]

December 2020...

Biopolitical Times

There Be Gold in Them Thar Genes

By Pete Shanks | 02.24.2021

We were shocked — shocked — to learn that 23andMe is cashing in on its customers’ spit. $3.5 billion...

Genomics

A Cloned Ferret!

By Pete Shanks | 02.24.2021

"Black-footed Ferret Kits" by USFWS Mountain Prairie
is licensed under CC BY 2.0

The New York Times published on February...

Animal Biotechnologies

New Data Confirm the Need to Regulate the US Assisted Reproduction Industry

By Pete Shanks | 02.10.2021

The United States fertility market is growing very rapidly, and is projected to reach $15.4 billion in 2023, more than double...

Genetic Selection

News

Response to Levrier re: Human Germline and Heritable Genome Editing: The Global Policy Landscape

By Marcy Darnovsky, Katie Hasson, and Timothy M. Krahn, The CRISPR Journal | 02.19.2021
Levrier apparently misunderstands the nature of our project published in The CRISPR Journal in October 2020.1 We identified and reviewed policy documents relevant to human germline and heritable genome editing research in 96 countries.
Policies

Novartis and the Gates Foundation aim to create a more practical gene therapy for sickle cell patients around the world

By Elizabeth Cooney, STAT | 02.17.2021

Image licensed under the CC BY 3.0

Novartis and the Bill and Melinda Gates Foundation are joining forces to discover and develop a gene therapy to cure sickle cell disease with a one-step, one-time treatment that is affordable and simple...

Human Genetic Modification

Bluebird suspends studies of sickle cell gene therapy following cancer diagnoses in two more treated patients

By Adam Feuerstein, STAT | 02.16.2021

Bluebird Bio said Tuesday that it has suspended clinical trials involving its gene therapy for sickle cell disease after receiving reports that two patients treated with the one-time therapy were diagnosed with cancer.

The trials were placed on “temporary suspension”...

Human Genetic Modification

Gene therapy trials for sickle cell disease halted after two patients develop cancer

By Jocelyn Kaiser, Science | 02.16.2021

A company has stopped its clinical studies of a promising gene therapy for the blood disorder sickle cell disease after two people who participated developed leukemia-like cancer. Bluebird bio is now investigating whether a virus it uses to deliver a...

Human Genetic Modification

Video
Use Gene Editing to Treat Patients, Not Design Babies
CRISPR: What is the future of gene editing? | Start Here
Climate Crisis, Designer Babies and Pandemics: Challenging the Techno-Utopianism of the Genetically Engineered Age